Affimed Unveils Updated Phase 1/2 Clinical Data on Afm13 and Cord Blood-Derived NK Cells at AACR 2024
Affimed presented updated clinical data from a Phase 1/2 study of Afm13, a treatment combined with cord blood-derived NK cells. This presentation occurred at the AACR Annual Meeting in November 2024.
The study focused on the safety and efficacy of Afm13 in patients with relapsed or refractory CD30-positive malignancies. Researchers reported positive results from the trial. The combination therapy showed promising response rates among the participants.
Researchers noted improvements in tumor reduction and overall patient outcomes. The treatment was well-tolerated, with manageable side effects.
What is Afm13 and how does it target CD30-positive cancers?
Interview with dr. Emily Thompson on the Latest advances in Cancer Therapy with Afm13 and NK Cells
Interviewer: Thank you for joining us today, Dr. Thompson. Can you share your insights on the recently presented clinical data regarding Afm13 combined with cord blood-derived NK cells?
Dr. emily Thompson: Absolutely,and thank you for having me. The recent update presented at the AACR Annual Meeting in November 2024 marks a significant step forward in the treatment of CD30-positive malignancies. This Phase 1/2 study evaluated the safety and efficacy of Afm13 in conjunction with NK cells derived from cord blood, and the results were quite promising.
interviewer: What were some of the key findings from this study?
Dr. Thompson: The researchers reported notable positive outcomes in terms of tumor reduction and overall patient responses. The combination therapy demonstrated high response rates among participants,which is encouraging for patients suffering from relapsed or refractory cancers. Moreover, the treatment was well-tolerated, with manageable side effects, which is a critical factor in cancer therapies.
Interviewer: How significant are these findings for the field of cancer treatment?
Dr. Thompson: These findings highlight a transformative potential in utilizing NK cells in cancer therapy. The ability to engage the innate immune system effectively is pivotal, particularly for patients who have weary other treatment options. The results from this study not only support the efficacy of Afm13 but also open doors for further research and larger clinical trials to confirm these initial observations.
Interviewer: What implications do these results have for future research and patient care?
Dr. Thompson: the positive results encourage us to delve deeper into this treatment modality.We can expect to see further exploration of this combination therapy in larger trials that could solidify our understanding and perhaps lead to new standards of care for patients with CD30-positive malignancies. Our ultimate goal is to enhance patient outcomes and provide more effective treatment options that are both safe and tolerable.
Interviewer: Thank you, Dr. Thompson, for sharing your expertise on this important topic. We look forward to seeing how this research develops in the future.
Dr. Thompson: Thank you for the prospect to discuss this exciting advancement in cancer therapy.
This study highlights the potential of using NK cells in cancer therapy. The findings encourage further exploration in larger trials.
In summary, Afm13 precomplexed with cord blood-derived NK cells shows promise for treating specific cancers. The ongoing research aims to confirm these initial results and improve patient care.